Previous Close | 63.37 |
Open | 64.33 |
Bid | 64.00 x 400 |
Ask | 64.45 x 400 |
Day's Range | 63.57 - 64.61 |
52 Week Range | 25.98 - 110.25 |
Volume | |
Avg. Volume | 1,989,049 |
Market Cap | 6.715B |
Beta (5Y Monthly) | 0.68 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.45 |
Earnings Date | May 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 93.88 |
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European Summer Time (11:00 AM Eastern Time) to discuss the primary results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), which are being presented in a Late Breaking Clinical Trial session at Heart Failure 2024, an Internation
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Invest